These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7847779)

  • 1. Iron transport and subcellular distribution in Hep G2 hepatocarcinoma cells.
    Parkes JG; Templeton DM
    Ann Clin Lab Sci; 1994; 24(6):509-20. PubMed ID: 7847779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells.
    Parkes JG; Randell EW; Olivieri NF; Templeton DM
    Biochim Biophys Acta; 1995 Apr; 1243(3):373-80. PubMed ID: 7727512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
    Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
    Chua AC; Ingram HA; Raymond KN; Baker E
    Eur J Biochem; 2003 Apr; 270(8):1689-98. PubMed ID: 12694182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.
    Link G; Pinson A; Hershko C
    Blood; 1994 May; 83(9):2692-7. PubMed ID: 8167347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
    Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
    Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
    Richardson DR; Ponka P
    J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study.
    Gaboriau F; Chantrel-Groussard K; Rakba N; Loyer P; Pasdeloup N; Hider RC; Brissot P; Lescoat G
    Biochem Pharmacol; 2004 Apr; 67(8):1479-87. PubMed ID: 15041465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D; Ponka P; Baker E
    Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin.
    Georgiou NA; van der Bruggen T; Oudshoorn M; Nottet HS; Marx JJ; van Asbeck BS
    J Infect Dis; 2000 Feb; 181(2):484-90. PubMed ID: 10669330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
    Florence A; Ward RJ; Peters TJ; Crichton RR
    Biochem Pharmacol; 1992 Sep; 44(6):1023-7. PubMed ID: 1417929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells.
    Link G; Konijn AM; Hershko C
    J Lab Clin Med; 1999 Feb; 133(2):179-88. PubMed ID: 9989770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferative effect of deferiprone on the Hep G2 cell line.
    Chenoufi N; Drénou B; Loréal O; Pigeon C; Brissot P; Lescoat G
    Biochem Pharmacol; 1998 Aug; 56(4):431-7. PubMed ID: 9763218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.